In response to “Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: Risk or opportunity?” - 10/08/11
Doi : 10.1016/j.jaad.2010.10.033
Amylynne Frankel, MD a, ⁎ 
, Abby S. Van Voorhees, MD b, Sylvia Hsu, MD c, Neil J. Korman, MD, PhD d, Mark Lebwohl, MD a, Bruce F. Bebo, PhD e, Alice Gottlieb, MD, PhD f
, Abby S. Van Voorhees, MD b, Sylvia Hsu, MD c, Neil J. Korman, MD, PhD d, Mark Lebwohl, MD a, Bruce F. Bebo, PhD e, Alice Gottlieb, MD, PhD f a Department of Dermatology, Mount Sinai School of Medicine, New York University, New York, New York
b Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
c Department of Dermatology, Baylor College of Medicine, Houston, Texas
d Department of Dermatology and the Murdough Family Center for Psoriasis, Case Western Reserve University/University Hospital of Cleveland, Cleveland, Ohio
e National Psoriasis Foundation, Portland, Oregon
f Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
Correspondence to: Amylynne Frankel, MD, 5 East 98th St, Box 1048, New York, NY 10029
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosures: Dr Van Voorhees has served as a consultant/speaker/advisor for Amgen, Abbott, Biogen, Centocor, Genentech, Incyte, Warner Chilcott, Connetics, VGX, and Xtrac; she has been an investigator for Amgen, Astellas Genentech, Warner Chilcott, Roche, Bristol Myers Squibb, and IDEC. She has served on a drug safety monitoring board for Synta. She also is a stockholder and owns stock option in Merck. Dr Hsu has been a consultant for Abbott, Amgen, Biogen Idex, Centocor, and Genentech. She has been a clinical investigator for Amgen and Centocor. Dr Korman has been a consultant, investigator, or speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Lebwohl has been a consultant for Abbott, Amgen, Astellas, Centocor, Genentech, UCB Pharma, Stiefel, Triax, Pharmaderm, Medicis, Novartis, and Warner Chilcott. He has been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Bebo is employed by the National Psoriasis Fundation. The Foundation receives unrestricted financial support from Abbott, Centocor, Amgen, Wyeth, Genentech, Astellas, Stiefel, Galderma, Warner Chilcott, and Photomedix. Almost all of Dr Gottlieb’s consulting and speaking fees are paid to Tufts Medical Center. Dr. Gottlieb is a member of the speakers bureau of Amgen Inc and Wyeth Pharmaceuticals; has current consulting/advisory board agreements with Amgen Inc, Centocor Inc, Wyeth Pharmaceuticals, Celgene Corp, Bristol Myers Squibb Co, Beiersdorf Inc, Warner Chilcott, Abbott, Roche, Sankyo, Medarex, Kemia, Celera, TEVA, Acetelion, UCB, Novo Nordisk, Almirall, Immune Control, RxClinical, Dermipsor Ltd, Can-Fite, Incyte, Corgentech, Magen Biosciences, Stieffel, and Puretech; Tufts Medical Center has received research/educational grants from Centocor Inc, Amgen Inc, Wyeth Pharmaceuticals, Immune Control, Celgene Corp, Pharmacare, Incyte, and Abbott. Dr Frankel has no conflicts of interest to declare. |
© 2010
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 64 - N° 4
P. 788-790 - avril 2011 Retour au numéro
Article précédent
- Predicting pain during and after Mohs micrographic surgery: The need to consider psychological factors
- Andrew G. Affleck
- Rifampicin and clindamycin for hidradenitis
- Dmitri Wall, Brian Kirby
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?